Rigel Pharmaceuticals Inc.'s preclinical work with IgE receptor inhibitors in respiratory mast cells to treat allergic asthma and other diseases netted the company a collaborative research and licensing deal with Pfizer Inc. - but the arrangement does not include Rigel's Phase II rhinitis drug, R112, which the big-pharma firm might scoop up later for more money. (BioWorld Today) Read More
